31 reports

  • GLOBAL RNAI TECHNOLOGY MARKET, BY REGION, 2014-2022 (IN USD MILLION)
  • NORTH AMERICAN RNAI TECHNOLOGY MARKET, 2014-2022 (IN USD MILLION)

RNAi Technology Market The market for RNAi technology is estimated to be USD 12.56 billion in 2016 and is expected to reach USD 31.52 billion by 2021, growing at a CAGR of 20.19% RNA interference (RNAi) is a natural process of treating forms of cancer and other diseases by post-transcriptional silencing of genes by small fragments...

  • RNAi Technology
  • World
  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics, Inc.
  • Sirna Therapeutics, Inc.

REASONS FOR DOING THIS STUDY The RNAi market is burgeoning and is one of the most watched markets in the pharmaceuticals industry.

  • Biological Therapy
  • RNAi Technology
  • World
  • Market Shares
  • Market Size

List of Tables Table ## Global RNAi Technologies Market By Region, Market Forecast (2013-2025) (US$ MN) Table ## Global RNAi Technologies Market By Application, Market Forecast (2013-2025) (US$ MN) Table ## Global RNAi Technologies Market B

  • RNAi Technology
  • APAC
  • World
  • Forecast
  • Market Size
  • Benitec Biopharma Ltd, Major Products and Services
  • Benitec Biopharma Ltd - Major Products and Services

Benitec Biopharma Ltd (BLT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats....

  • Biopharmaceutical
  • Hepatitis
  • RNAi Technology
  • Therapy
  • Benitec Biopharma Limited
  • Deal Type
  • Dicerna Pharma Enters Into Licensing Agreement With Plant Bioscience For Baulcombe & Hamilton RNAi Patents

It offers RNAi technology platform GalXCTM, which is a advances the development of next-generation RNAi-based therapies that is designed to silence disease-driving genes in the liver.

  • Healthcare
  • Pharmaceutical
  • RNAi Technology
  • Therapy
  • Dicerna Pharmaceuticals, Inc.
  • DEAL TYPE
  • DEAL TYPE

The therapy is based on DNA-directed RNA interference (ddRNAi) technology.

  • Biopharmaceutical
  • Healthcare
  • RNAi Technology
  • Therapy
  • Benitec Biopharma Limited
  • OTHER LOCATIONS & SUBSIDIARIES

We are highly committed and motivated by the potential of RNAi based therapies using our GalNAc-siRNA technology.

  • Pharmaceutical
  • RNAi Technology
  • Therapy
  • United Kingdom
  • Silence Therapeutics
  • LICENSING AGREEMENTS
  • FEB 07, 2017: RXI PHARMACEUTICALS APPOINTS LEADING ONCOLOGY EXPERT, DR. ROLF KIESSLING, TO SCIENTIFIC ADVISORY BOARD

" RXi Pharmaceuticals' self-delivering RNAi (sd-rxRNA) technology is one of the most innovative developments in the space, " said Dr.

  • RNAi Technology
  • Therapy
  • United States
  • Company Operations
  • RXi Pharmaceuticals Corporation
  • Proliferative Vitreoretinopathy (PVR) - Drug Profiles

The company uses RNAi and sd-rxRNA technologies for the development of products.

  • RNAi Technology
  • Therapy
  • United States
  • Product Initiative
  • RXi Pharmaceuticals Corporation

Arcturus Therapeutics now owns the UNA technology patent estate, enabling the company to operate freely and to independently pursue RNAi therapeutics.

  • Pharmaceutical
  • RNAi Technology
  • Therapy
  • United States
  • Arcturus Therapeutics, Inc.
  • ALNYLAM PHARMA ENTERS INTO LICENSING AGREEMENT WITH ASCLETIS PHARMA (HANGZHOU) TO DEVELOP ALN-VSP
  • ALNYLAM PHARMA AND GENZYME ENTER INTO AGREEMENT FOR RNAI THERAPEUTICS AS GENETIC MEDICINES

The drug candidate is developed based on RNAi Technology and LNP technology.

  • Pharmaceutical
  • RNA Interference
  • RNAi Technology
  • Therapy
  • Alnylam Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals Inc - History

In April, Alnylam entered into a new collaboration agreement with Isis Pharmaceuticals, Inc. for the development of Single-Stranded RNAi Technology.

  • Pharmaceutical
  • RNA Interference
  • RNAi Technology
  • Therapy
  • Alnylam Pharmaceuticals, Inc.

Arcturus Therapeutics owns the UNA technology patent estate, enabling Marina Biotech to operate freely and to independently pursue RNAi therapeutics.

  • Biotech
  • RNAi Technology
  • United States
  • Company
  • Marina Biotech, Inc.

Agrow: RNAi

2709 2980 2303

It details company and product profiles, and activities and pipelines of specialist companies and research institutes engaged in RNAi technology.

  • Biological Therapy
  • RNA Interference
  • RNAi Technology
  • United States
  • Litigation And Patent

About Dicer Substrate Technology Dicerna' s proprietary RNAi molecules are known as Dicer substrates, or DsiRNAs, so called because they are processed by the Dicer enzyme, which is the initiation point for RNAi in the human cell cytoplasm.

  • Biotech
  • RNAi Technology
  • World
  • Product Initiative
  • Marina Biotech, Inc.

No Development Reported in Cancer Drugs in Clinical Pipeline ##. ## RNA Interference-Based Technology – Alnylam ##. ## RNAi Therapeutics - Alnylam/ University of California San Francisco ##.

  • Biological Therapy
  • Pharmaceutical
  • RNAi Technology
  • Therapy
  • United States

This grant will be used for the development of Single Strand RNAi Technology Platform.

  • RNAi Technology
  • United States
  • Corporate Finance
  • M&A
  • Alnylam Pharmaceuticals, Inc.
  • RNAI OLIGONUCLEOTIDES FOR NASH, CARDIOVASCULAR AND METABOLIC DISORDERS
  • RNAI OLIGONUCLEOTIDES FOR GENETIC DISEASES

Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘Alnylam Pharmaceuticals, Inc. - Product Pipeline Review, 2016’, provides an overview of the Alnylam Pharmaceuticals, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information...

  • Pharmaceutical
  • Research And Development
  • RNAi Technology
  • Therapy
  • Alnylam Pharmaceuticals, Inc.

Roche will use Tekmira' s SNALP technology for two RNAi product candidates.

  • Biopharmaceutical
  • Pharmaceutical
  • RNAi Technology
  • Therapy
  • Arbutus Biopharma Corporation
  • DEC 19, 2017: SOMAGENICS RECEIVES AWARD OR ALLOWANCE OF FOUR PATENTS COVERING ITS SMALL RNA ANALYSIS AND THERAPEUTICS

The third issued patent, US ##, ##, ##, broadens coverage for chemical modifications of SomaGenics' proprietary RNAi technology, short small hairpin RNA (sshRNA®).

  • RNA
  • RNAi Technology
  • United States
  • Company Operations
  • SomaGenics, Inc.
  • Key Information
  • Product Description

Benitec Biopharma Limited - Product Pipeline Review - 2015 Summary Global Markets Direct’s, ‘Benitec Biopharma Limited - Product Pipeline Review - 2015’, provides an overview of the Benitec Biopharma Limited’s pharmaceutical research and development focus. This report provides comprehensive information on the current...

  • Biopharmaceutical
  • Hepatitis
  • RNAi Technology
  • Therapy
  • Benitec Biopharma Limited

Further key findings from the report suggest: • RNA interference technology accounted for the largest share in market revenue in 2016 owing to advantages associated with this technology over antisense technology • Based on the triggering of RNA molecules this

  • Biological Therapy
  • RNAi Technology
  • Therapy
  • United States
  • Market Size
  • STP-703
  • STP-911

Sirnaomics, Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘Sirnaomics, Inc. - Product Pipeline Review - 2016’, provides an overview of the Sirnaomics, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development...

  • RNAi Technology
  • China
  • United States
  • Company Operations
  • Sirnaomics, Inc.

RNAi for Therapeutic Applications: Technology and Market Forecast 2015-2025: Prospects for siRNAs, shRNAs and ddRNAi Approaches Table of Contents ##.

  • Biological Therapy
  • RNA Interference
  • RNAi Technology
  • World
  • Market Size

Roche will use Tekmira' s SNALP technology for two RNAi product candidates.

  • RNAi Technology
  • United States
  • Company
  • Corporate Finance
  • Tekmira Pharmaceuticals Corporation
  • RXI PHARMACEUTICALS CORPORATION - DRUG PROFILES

The drug therapy is developed on RNA interference (RNAi) technology.

  • RNA Interference
  • RNAi Technology
  • United States
  • Company Operations
  • RXi Pharmaceuticals Corporation

The novel acquired technologies potentially enable in-vivo delivery of RNAi therapeutics.

  • Pharmaceutical
  • RNAi Technology
  • United States
  • Corporate Finance
  • Galena Biopharma, Inc.

It uses RNAi and sd-rxRNA technologies for the development of products.

  • Research And Development
  • RNAi Technology
  • United States
  • Company Operations
  • RXi Pharmaceuticals Corporation

Deal in brief Company information: Partners Partner ##: Agilent Technologies, Inc.

  • RNAi Technology
  • Therapy
  • United States
  • Corporate Finance
  • Silence Therapeutics

## RNAI AS THERAPY ## THE PROMISE OF RNAI ## TABLE ## VARIOUS TECHNOLOGIES FOR GENE SUPPRESSION ## RNAI TECHNOLOGY ## RNAI MECHANISM: HOW DOES IT WORK?

  • Biological Therapy
  • RNAi
  • RNAi Technology
  • World
  • Forecast